furosemide acetamide cocrystal | 1356162-54-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: furosemide acetamide cocrystal
• 英文别名: Acetamide;4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
• CAS: 1356162-54-3
• 化学式: C₂H₅NO*C₁₂H₁₁ClN₂O₅S
• 分子量: 389.817
• InChiKey: JMLPGHJACDHRCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.38
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  174
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  乙酰胺 、 呋塞米 以 乙腈 为溶剂， 反应 0.33h， 生成 furosemide acetamide cocrystal
  参考文献：
  名称：

  新型呋塞米共晶体和高溶解度药物形式的选择

  摘要：

  在与药学上可接受的共形成分子共结晶实验中筛选了呋塞米，以发现具有改善的物理化学性质的共晶体，即高溶解度和良好的稳定性。通过与（i）咖啡因，（ii）尿素，（iii）对氨基苯甲酸，（iv）乙酰胺，（v）烟酰胺，（vi）异烟酰胺，（vii）进行液体辅助研磨，获得了速尿的八种新型等摩尔共结晶。腺嘌呤和（viii）胞嘧啶。通过粉末X射线衍射，差示扫描量热法，红外，拉曼，近红外和（13）固态NMR光谱对产物的结晶相进行表征。通过单晶X射线衍射将速尿-咖啡因表征为中性共晶，将速尿-胞嘧啶表征为离子盐。速尿-咖啡因，速尿-腺嘌呤，速尿-胞嘧啶在10％乙醇-水浆液中与参考药物相当; 在长达48小时内，没有证据表明共结晶离解成速尿。其他五个共晶体在24小时内转化为呋塞米。稳定形式的溶解度顺序为速尿-胞嘧啶>速尿-腺嘌呤>速尿-咖啡因，其溶解度比速尿高11-，7-和6倍。速尿共晶体的溶解速率比纯药物快约两倍。在

  DOI：

  10.1002/jps.22805

文献信息

• BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
  申请人：Wanaski Stephen

  公开号：US20120004225A1

  公开（公告）日：2012-01-05

  The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  本发明提供了丁苯噻唑、呋塞米、匹利他酯、氮杂呋喃硫脲和托瑞米特的类似物以及包含这些类似物的组合物。本发明还提供了含有这些丁苯噻唑、呋塞米、匹利他酯、氮杂呋喃硫脲和托瑞米特类似物的药物组合物以及它们的使用方法。所有这些类似物特别适用于治疗和/或预防涉及Na+K+Cl−共转运体或GABAA受体的疾病，包括但不限于成瘾障碍、阿尔茨海默病、焦虑障碍、腹水、自闭症、躁郁症、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、失眠、缺血、偏头痛、带前兆的偏头痛、神经痛、伤害性神经痛、眼部疾病、疼痛、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫、耳鸣和戒断综合症。
• BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
  申请人：NeuroPro Therapeutics, Inc.

  公开号：US20150080350A1

  公开（公告）日：2015-03-19

  The present invention provides bumetanide, analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma. Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  本发明提供了丁苯酞、类似物和包含这些类似物的组合物。本发明还提供了含有这些丁苯酞、类似物的药物组合物以及它们的使用方法。这些类似物特别适用于治疗和/或预防涉及Na+K+Cl−共转运体或GABAA受体的疾病，包括但不限于成瘾性障碍、阿尔茨海默病、焦虑症、腹水、自闭症、双相情感障碍、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、失眠症、缺血、偏头痛、伴有先兆的偏头痛、神经痛、痛觉性神经痛、眼部疾病、疼痛、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫、耳鸣和戒断综合征。
• BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE
  申请人：NeuroPro Therapeutics, Inc.

  公开号：US20170246131A1

  公开（公告）日：2017-08-31

  The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor.
• BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE
  申请人：NeuroPro Therapeutics, Inc.

  公开号：US20190151263A1

  公开（公告）日：2019-05-23

  The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor.
• US9682928B2
  申请人：——

  公开号：US9682928B2

  公开（公告）日：2017-06-20